130 related articles for article (PubMed ID: 12377638)
1. Is cisplatin still the best platinum compound in non-small-cell lung cancer?
Soria JC; Le Chevalier T
Ann Oncol; 2002 Oct; 13(10):1515-7. PubMed ID: 12377638
[No Abstract] [Full Text] [Related]
2. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
4. [Current data concerning neoadjuvant chemotherapy].
Depierre A
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S11-3. PubMed ID: 16719148
[No Abstract] [Full Text] [Related]
5. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
6. Platinums in lung cancer: sufficient or necessary?
Bunn PA
J Clin Oncol; 2005 May; 23(13):2882-3. PubMed ID: 15728220
[No Abstract] [Full Text] [Related]
7. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
Socinski MA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4210s-4214s. PubMed ID: 15217960
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Postmus P
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S48-50. PubMed ID: 12538936
[No Abstract] [Full Text] [Related]
10. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
Gatzemeier U; von Pawel J; Gottfried M; ten Velde GP; Mattson K; de Marinis F; Harper P; Salvati F; Robinet G; Lucenti A; Bogaerts J; Gallant G
J Clin Oncol; 2000 Oct; 18(19):3390-9. PubMed ID: 11013280
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy should be standard of care for lung cancer.
Oncology (Williston Park); 2002 Jul; 16(7):962, 986. PubMed ID: 12164561
[No Abstract] [Full Text] [Related]
13. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
15. Can Carboplatin replace Cisplatin in small cell lung cancer?
Noronha V
Indian J Cancer; 2011; 48(4):452-3. PubMed ID: 22293259
[No Abstract] [Full Text] [Related]
16. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
17. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
Tiseo M; Boni L; Ardizzoni A
J Clin Oncol; 2005 Sep; 23(25):6276-7; author reply 6277-8. PubMed ID: 16135504
[No Abstract] [Full Text] [Related]
18. Treatment of advanced non-small-cell lung cancer in special populations.
Lilenbaum RC
Oncology (Williston Park); 2004 Sep; 18(10):1321-5; discussion 1326, 1329-33. PubMed ID: 15526837
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
Rosell R; Gatzemeier U; Betticher DC; Keppler U; Macha HN; Pirker R; Berthet P; Breau JL; Lianes P; Nicholson M; Ardizzoni A; Chemaissani A; Bogaerts J; Gallant G
Ann Oncol; 2002 Oct; 13(10):1539-49. PubMed ID: 12377641
[TBL] [Abstract][Full Text] [Related]
20. Successful switch to cisplatin-based chemotherapy in a patient with lung cancer who developed a carboplatin-induced hypersensitivity reaction.
Nagata Y; Toyokawa G; Sugiyama A; Shimamatsu S; Saitoh O; Okubo H; Ueda H
J Oncol Pharm Pract; 2024 Jun; 30(4):772-776. PubMed ID: 38404012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
